tebu-bio’s latest Travel Grant draw took place on June 16th, and saw six more researchers win 400 Euros each towards attending the meeting of their choice.

Here’s some news from two of our previous winners (in October 2016 and February 2017), who were happy to share these pictures from the same meeting they both attended!

27th European Congress of Clinical Microbiology and Infectious Diseases – Vienna, Austria –  April 2017

Dr Giuliana Banche of the University of Torino (Italy) presenting her research.

Beatriz Rojo of the CIBIR (Spain), presenting her research.

Interested in winning 400 euros for your next meeting?

tebu-bio’s fourth and final draw for 2017 will take place in October, applications are now open and can be uploaded online here.

Neutralizing MAb Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 – PBL Assay Sciences at tebu-bio

PBL Assay Sciences offer a new monoclonal antibody to neutralize Human Interferon (IFN) activity, the Anti-Human Interferon Lambda Receptor 1, Clone MMHLR-1 (MAb).

This antibody is suitable for use in Type III IFN neutralization, flow cytometry, immunohistochemistry and immunoprecipitation. It neutralizes biological activity of human Type III IFNs (IFN lambda 1, 2 & 3, i.e. IL-29, IL-28A & IL-28B, respectively) at the Lambda Receptor 1 (i.e. IL-28 Receptor 1), and blocks Type I interferon receptor complex.

This complements the existing offer of antibodies and proteins to neutralize human and mouse IFN activities, available across Europe through tebu-bio’s network of local offices.

This slideshow requires JavaScript.

Raising funds to travel to your scientific meetings is often challenging. To help researchers present and share their work, tebu-bio’s long-standing Travel Grant scheme offers the possibility to get 400 euros towards participating in meetings and conferences anywhere in the world.

Applications are accepted online, and are open to all researchers working in Life Sciences labs in Europe. In 2016, there have already been three draws, with 6 winners for each draw. The fourth and final draw for this year will take place on October 7th, for which applications will close on October 5th.

Interested? You’ll find full details to apply for your travel grant on-line here.

Live Cell Imaging tools by tebu-bio

Visualizing fixed cells and tissues only gives snap shots of cellular processes. Over the past years, more and more cellular parameters have become measurable in living cells.  For this purpose, there is a growing number of specific stains capable of entering the cell without any toxic effects, which could also negatively impact the parameters to be measured.

Accessing a full range of tools for live cell imaging is important, and especially useful if everything is available in one place… Researchers interested in exploring what’s available can use this new webpage put together by tebu-bio, including some of the most recent and innovative tools (such as the increasingly popular SiR actin and SiR tubulin stains).

By simply clicking on the chosen area of a cell, all related reagents available are displayed.
A useful tool for accessing a large number of items for your Live Cell Imagaing in one place!

Access the Live Cell Imagaing Tools page for more details.

This week, the 13th European ISSX (International Society for the Study of Xenobiotics) meeting is taking place in Glasgow (Scotland) at the University of Strathclyde.

The meeting brings scientists together during courses, keynote sessions, poster sessions and much more.

One of this blog’s authors, Jean-François, is attending as Cells & ADME-Tox specialist at tebu-bio.

If you’re there (or know anyone that is…) stop by booth 102 to say hello!

 Follow live tweets with #ISSX

tebu-bio recently signed an agreement with Enzium Inc. (Philadelphia, PA, USA) for the distribution in Europe of their protease activity assays.

Enzium has developed a new approach to measure the activity of proteases such as diverse MMPs, ADAMs, Thrombin, Factor Xa, and Furin and the inhibitory effects of drug candidates.

Dr. Diana Hulboy (VP, Marketing and Business Development at Enzium) says: “We are thrilled to collaborate with tebu-bio on the marketing of EnSens® assays throughout the European community, as we believe our new, non-FRET fluorescent technology will change how researchers think about protease activity detection.”

Dr. Ali El Bayâ (tebu-bio, Sales Manager – Proteins & Protein based Products & Services) adds “Enzium’s EnSens® technology is a very promising alternative to classical FRET based protease assays which are used in screenings in drug discovery. The benefits of this new approach in terms of lower signal to noise ratio and higher flexibility in creating longer and more complex protease recognition sites seem obvious to us. We are sure our extensive customer base within the drug discovery community will be keen to use this technology.”

Contact your local tebu-bio office to discuss further about your protease assays.

tebu-bio (Le Perray en Yvelines, France) recently announced their agreement with HemaCare (Van Nuys, CA USA) to provide their range of biological blood products throughout Europe.

HemaCare is a leader in cell and tissue collection, processing and cell therapy, providing high-quality biological material derived from normal and mobilized peripheral blood, bone marrow and cord blood.

Jean-François Têtu (Sales Manager – Cells & Cell Based Assays at tebu-bio) says “By signing this agreement with HemaCare, tebu-bio is pleased to again enlarge our range of sourcing possibilities. I am proud to say that, more than ever, our commitment to source the very cell type that fits the researcher’s needs is true.”

With HemaCare as the latest addition to their offer, tebu-bio now offers European researchers access to highly pure and characterized primary human cells and blood components collected from IRB consented normal donors and patients.  The samples are available through an extensive registry but also collected  on demand, with donors matching researchers’ specifications. tebu-bio’s well-established logistics ressources make shipment of cryopreserved and fresh samples all over Europe possible, literally from donors to researchers.

For more information on HemaCare’s products now available in Europe, contact Jean-François Têtu or visit tebu-bio.com.